SWAM机械取栓系统与AngioJet流变取栓系统治疗急性下肢深静脉血栓的前瞻性随机单中心研究
该前瞻性随机单中心研究纳入290例急性下肢DVT患者,1:1比较SWAM与AngioJet机械取栓系统。SWAM组血栓清除III级率与AngioJet相当,但手术时间更短、尿激酶用量更少、症状性PE发生率更低、溶血指标显著改善。
要点
- SWAM与AngioJet的III级血栓清除率无显著差异(78.6% vs 72.4%,P=0.221)。
- SWAM组手术时间和尿激酶用量均显著低于AngioJet组(P<0.001)。
- SWAM组症状性PE发生率和溶血指标均显著低于AngioJet组。
核心结论
- SWAM系统在急性下肢DVT中血栓清除效果与AngioJet相当,且手术时间更短、溶栓药物用量更少、症状性PE发生率更低、溶血显著减轻。
研究设计与样本
- 前瞻性随机单中心研究,2022年1月至2024年12月纳入290例急性下肢DVT患者(症状持续时间≤14天),1:1随机分为SWAM组(n=145)和AngioJet组(n=145)。
- 主要终点为完成静脉造影评估的血栓清除分级(I-III级);次要终点包括手术时间、尿激酶剂量、症状性PE发生率、溶血指标(血浆游离血红蛋白)和6个月一期通畅率。
主要发现
- SWAM组III级血栓清除率为78.6%,AngioJet组为72.4%(P=0.221)。
- SWAM组手术时间显著短于AngioJet组(42.3±12.7 vs 58.6±15.4 min;P<0.001)。
- SWAM组尿激酶用量显著低于AngioJet组(150,000±50,000 vs 350,000±100,000 IU;P<0.001)。
- SWAM组症状性PE发生率为1.4%,AngioJet组为5.5%(P=0.048)。
- SWAM组术后血浆游离血红蛋白水平显著低于AngioJet组(112.4±45.3 vs 438.7±168.5 mg/dL;P<0.001)。
临床怎么用
- 对于急性下肢DVT(症状≤14天)行经皮机械取栓,SWAM系统可作为AngioJet的安全有效替代方案。
局限性
- 单中心研究设计可能限制结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute lower extremity deep vein thrombosis (DVT) poses a significant clinical burden due to its association with post-thrombotic syndrome and pulmonary embolism (PE). While the AngioJet rheolytic thrombectomy system has established clinical utility, device-related hemolysis and embolic complications remain concerns. The Zhongtian SWAM (Synchronized Wave Aspiration and Maceration) system represents an innovative mechanical thrombectomy technology designed to minimize these adverse effects. OBJECTIVE: To compare the clinical efficacy and safety profile of the Zhongtian SWAM mechanical thrombectomy system versus the AngioJet rheolytic thrombectomy system in patients with acute lower extremity DVT in a prospective, randomized trial. METHODS: Between January 2022 and December 2024, 290 patients with acute lower extremity DVT (symptom duration ≤14 days) were randomized 1:1 to the SWAM group (n = 145) or the AngioJet group (n = 145). The primary endpoint was thrombus clearance grade (I-III) assessed by completion venography. Secondary endpoints included procedural time, urokinase dose, symptomatic PE incidence, hemolytic indices (plasma-free hemoglobin [PfHgb]), and 6-month primary patency. RESULTS: Grade III thrombus clearance was achieved in 78.6% of the SWAM patients versus 72.4% of the AngioJet patients (P = 0.221). Procedural time was significantly shorter in the SWAM group (42.3 ± 12.7 vs. 58.6 ± 15.4 min; P < 0.001). Urokinase consumption was markedly reduced in the SWAM group (150,000 ± 50,000 vs. 350,000 ± 100,000 IU; P < 0.001). Symptomatic PE occurred in 1.4% versus 5.5% of the patients (P = 0.048). Post-procedural PfHgb levels were substantially lower in the SWAM group (112.4 ± 45.3 vs. 438.7 ± 168.5 mg/dL; P < 0.001). Six-month primary patency was 91.0% versus 86.2% (P = 0.152). CONCLUSION: The Zhongtian SWAM system achieved comparable thrombus clearance to the AngioJet system with significantly shorter procedural time, reduced thrombolytic drug use, lower PE incidence, and markedly attenuated hemolysis. These findings support the SWAM system as a safe and effective alternative for percutaneous mechanical thrombectomy in acute lower extremity DVT.
引用
- Zou H, Zhao Y, Ji Z, et al. SWAM Mechanical Thrombectomy System Versus AngioJet Rheolytic Thrombectomy System for Acute Lower Extremity Deep Vein Thrombosis: A Prospective, Randomized, Single-Center Study. Ann Vasc Surg. 2026. PMID: 42575266. doi:10.1016/j.avsg.2026.07.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。